



Regd. Office:

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.

Phone: +91-79-2686 8100 (20 Lines) Fax: +91-79-2686 2368

CIN:L24230GJ1995PLC025878

www.zyduscadila.com

July 19, 2017

BSE Limited

1st Floor, P J Towers, Dalal Street, Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Re.: Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated July 19, 2017 titled "Zydus launches Mesalamine Delayed Release Tablets in the US".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, CADILA HEALTHCARE LIMITED

UPEN H. SHAH

COMPANY SECRETARY

Di



Press Release

Press lelease

Zydus launches Mesalamine Delayed Release Tablets in the US

Ahmedabad, 19 July 2017

Zydus Cadila has commercially launched its Mesalamine Delayed Release Tablets USP, 1.2g in the US market. Zydus was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda® and is currently the only generic available to patients in the US. The drug is indicated for the treatment of mild to moderate ulcerative colitis which affects approximately 700,000 people within the US. The group has received 26 final ANDA approvals from the USFDA and 2 tentative ANDA approvals since January 2017. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

###